Cytoplasmic elongation and rupture in megakaryoblastic leukemia cells via activation of adhesion and motility by staurosporine on fibronectin-bound substratum.
Human megakaryoblastic leukemia Meg-01 cells were attached to fibronectin (FN)-coated substratum, on which remarkable spreading and cytoplasmic elongation was induced by treatment with a protein kinase inhibitor, staurosporine (stp). This effect was inhibited by RGDS and was also not seen on FN-lacking substratum. The extended cytoplasm had swollen terminals and nodes, which contained GpIIb and beta-thromboglobulin, occasionally included alpha granules, and tended to form particles (2-5 microm) after rupture of the narrowed cytoplasm. Among other protein kinase modulators tested, only K252a promoted the elongation, while calphostin, herbimycin, TPA, and calyculin suppressed it. The cells began to migrate soon after addition of stp, with attachment to the substratum held at some sites during the migration. This tethered movement seemed to cause the cytoplasmic elongation and the rupture into particles. The elongation was retarded by pretreating the cells with cytochalasin A and Clostridium C3 toxin but not with demecolcine. Actin microfilaments in the stp-treated Meg-01 cells accumulated in the filopodia and periphery of the extended cytoplasm, in which vinculin was colocalized as adhesion plaques. The microtubules were longitudinally oriented through the cytoplasmic extension and showed no ring profile in the nodes and particles. Thus, stp in the presence of FN appears to stimulate reorganization of actin-based cytoskeleton and formation of focal contacts in Meg-01 cells. This leads to the activation of cell adhesion and motility, and then cytoplasmic elongation and rupture into particles.
Yamazaki
Y
Y
National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Tsukuba, Ibaraki, Japan. yamazaki@nibh.go.jp
Sanokawa
R
R
Fujita
Y
Y
Zhou
D
D
Kawasaki
K
K
Tanaka
H
H
Komatsu
T
T
Nagasawa
T
T
Oka
S
S
D000818:Animals; D001427:Bacterial Toxins / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D003572:Cytochalasins / Q000494:pharmacology; D003703:Demecolcine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005353:Fibronectins / Q000494:pharmacology*; D007947:Leukemia, Megakaryoblastic, Acute / Q000473:pathology*; D051379:Mice; D008854:Microscopy, Electron; D009842:Oligopeptides / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D019311:Staurosporine / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D001427:Bacterial Toxins; D003572:Cytochalasins; D004791:Enzyme Inhibitors; D005353:Fibronectins; D009842:Oligopeptides; D047428:Protein Kinase Inhibitors; C031218:cytochalasin A; C046617:arginyl-glycyl-aspartyl-serine; D019311:Staurosporine; D003703:Demecolcine